drugset / Trial / NCT06366932
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to cyclosporine.
Timeline
- Start
- 2023-09-25
- Primary completion
- 2025-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abrocitinib | Small molecule | — | — |
| Subject | Baricitinib | Small molecule | — | — |
| Subject | Dupilumab | Monoclonal antibody | — | — |
| Subject | Tralokinumab | Monoclonal antibody | — | — |
| Subject | Upadacitinib | Small molecule | — | — |